Pharmaceuticals, Biotechnology and Life Sciences
Roche’s cancer drug Tecentriq hit the market months behind immuno-oncology (I/O) medicines from Merck and Bristol-Myers Squibb Co but the Swiss drugmaker’s treatment is making up lost ground.
U.S. President-elect Donald Trump on Wednesday said pharmaceutical companies are “getting away with murder” in what they charge the government for medicines, and promised that would change, sending drugs stocks sharply lower.
Roche said on Monday that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizumab) for metastatic urothelial carcinoma (mUC).
Roche’s phase III study of haemophilia drug emicizumab prophylacis for 12 yearolds and older has met its primary endpoint, as…
Alvogen on Monday launched the first flu capsules, generic equivalent to Roche’s Tamiflu (oseltamivir phosphate) capsules in the United States.
October is Breast Cancer Awareness Month, a worldwide annual campaign involving thousands of organizations, to highlight the importance of breast awareness, education and research.
The Swiss-based pharmaceutical major Roche has see a sales growth for the first three quarters of 2016, praising good performance of Tecentriq, it’s anti PD-L1 cancer immunotherapy that was approved for non-small cell lung cancerby the US FDA in May this year.
FDA approves Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for people with a specific type of metastatic lung cancer.
Cancer drug maker Roche followed Swiss rival Novartis in disappointing shareholders with a muted forecast for the year, sending its shares lower on Thursday.
Glenmark confirms reaching agreement with Roche over patent disputes